There is no vaccine for respiratory syncytial virus (RSV), which causes 177,000 hospitalizations and 14,000 deaths each year in adults older than 65. But early data from Novavax's Phase II trial of its RSV candidate show its promise in protecting older adults.
Novavax shares surged today on the news that its vaccine for respiratory syncytial virus (RSV) proved effective in a large midstage study that company officials billed as a "historic" achievement.
Novavax is making waves in the influenza space, reporting positive Phase II results for its quadrivalent seasonal flu vaccine on Thursday.
Back in February, Novavax took its Ebola candidate to Australia for a Phase I trial. The company reported positive top-line results from the 230-person trial on Tuesday.
Novavax announced on Thursday that it would take its Ebola candidate to Australia for a Phase I trial involving 230 healthy adults. It is the fourth company to bring an Ebola vaccine to human trials, but Novavax says it has a better vaccine.
Right now, the U.S. government is in search of an H7N9 vaccine that can reach the market to help prevent against a potential pandemic. And a new FDA fast-track designation for Novavax's candidate might help it get there a little sooner.
With several companies now expediting Ebola vaccines in an attempt to halt the spread of the deadly virus, Novavax has jumped in the race, announcing that it's using its nanoparticle vaccine technology to advance a candidate of its own.
Last month, critics questioned whether developing a vaccine for Middle East respiratory syndrome made any real sense for governments or vaccinemakers. But fast-forward a few weeks and everyone seems to be paying a little more attention.
As the death toll from Middle East respiratory syndrome coronavirus rises in Saudi Arabia, a vaccine designed by Novavax and the University of Maryland has shown promise in blocking the infection in animals.
Researchers at Kansas State University think they've found an existing antiviral drug that could squelch the H7N9 flu.